Adjuvant osimertinib demonstrated a statistically significant and clinically meaningful benefit for patients with stage IB, II, or IIIA *EGFR*-mutant non-small cell lung cancer (NSCLC) with complete tumour resection in the phase 3 ADAURA trial, presented by Prof. Roy Herbst (Yale Cancer Center, USA) .
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with demonstrated efficacy as a frontline agent for metastatic NSCLC with confirmed *EGFR*-mutation . The phase 3 ADAURA clinical trial attempted to assess whether this agent is also effective in earlier stages of metastatic disease characterised by *EGFR* mutation, namely as an adjuvant therapy after complete surgical resection of stage IB, II, or IIIA disease.
Oral osimertinib (80 mg, once daily) was compared with placebo for a treatment duration of up to 3 years or until disease...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Superior efficacy ponesimod vs teriflunomide in OPTIMUM study Next Article
Urothelial cancer: avelumab works as maintenance therapy »
Table of Contents: ASCO 2020
COVID-19 & Telemedicine
Breast & Ovarian Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.